Skip to main content
Premium Trial:

Request an Annual Quote

Pretty Vaccine Penny

Analysts estimate that Pfizer and BioNTech could make nearly $13 billion from global sales of their SARS-CoV-2 vaccine, the Guardian reports.

The companies reported earlier this week that initial data from their late-stage clinical trial of a candidate mRNA-based vaccine shows it is highly effective. The companies additionally said they planned to submit an Emergency Use Authorization application for the vaccine to the US Food and Drug Administration later this month.

According to Fox Business, the US has ordered 100 million doses, with the option of procuring 500 million more, while the European Union has ordered 200 million doses with the possibility of 100 million more. Meanwhile, the UK has ordered 30 million doses and Japan 120 million. The US deal, it adds, is worth $1.95 billion, or $19.50 per dose, as the Guardian notes.

The Guardian adds that some vaccine developers like Johnson & Johnson and AstraZeneca have pledged to not profit from their vaccines, as, for instance, AstraZeneca is charging governments between $3 and $5 per dose of its vaccine. But it notes that Pfizer — which turned down US federal funding — has not.